Sildenafil
- Generic Name
- Sildenafil
- Brand Names
- Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O4S
- CAS Number
- 139755-83-2
- Unique Ingredient Identifier
- 3M7OB98Y7H
- Background
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...
- Indication
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:
(1) the treatment of erectile dysfunction ; and
(2) treatment of pulmonary hypertension, where:
...
- Associated Conditions
- Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT05684289
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
🇺🇸Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 21
- Registration Number
- NCT05669885
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Denmark
Clinical Study to Evaluate the Possible Efficacy and Safety of L- Carnitine and Sildenafil in Children Having Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT05584956
- Locations
- 🇪🇬
Tanta University Hospital, Tanta, Gharbia, Egypt
Finding Solutions to Thrive After Birth Asphyxia in Africa
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Pia Wintermark
- Target Recruit Count
- 30
- Registration Number
- NCT05275725
- Locations
- 🇺🇬
Kawempe National Referral Hospital, Kawempe, Uganda
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT04994860
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Strategic Science & Technologies, LLC
- Target Recruit Count
- 440
- Registration Number
- NCT04948151
- Locations
- 🇺🇸
Coastal Connecticut Research, LLC, New London, Connecticut, United States
🇺🇸Intimmedicine Specialists, Washington, District of Columbia, United States
🇺🇸Southern Institute for Women's Sexual Health, Covington, Louisiana, United States
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT04797286
- Locations
- 🇺🇸
Louisiana State University, New Orleans, Louisiana, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Copd Exacerbation and Pulmonary Hypertension Trial
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2023-09-01
- Target Recruit Count
- 2
- Registration Number
- NCT04538976
- Locations
- 🇩🇰
Bispebjerg University Hospital, Copenhagen, Denmark
🇩🇰Herlev-Gentofte Hospital, Copenhagen, Denmark
🇩🇰Hvidovre Hospital, Copenhagen, Denmark
Sildenafil in COVID-19
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Universidad Nacional Andres Bello
- Target Recruit Count
- 40
- Registration Number
- NCT04489446
- Locations
- 🇨🇱
Hospital Naval Almirante Nef, Viña Del Mar, Valparaiso, Chile
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT04481789
- Locations
- 🇯🇵
Investigational site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.